Humacyte (HUMA) Research & Development (2020 - 2026)
Humacyte (HUMA) posted quarterly Research & Development of $19.5 million for Q1 2026, up 26.23% year-over-year from $15.4 million in Q1 2025, and up 33.26% quarter-over-quarter from $14.6 million in Q4 2025.
Humacyte (HUMA) Research & Development (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Research & Development for 7 consecutive years, with $19.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 26.23% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $73.3 million (down 11.37% YoY), while the FY2025 annual figure was $69.3 million, down 21.78% from the prior year.
- Research & Development climbed to $19.5 million in Q1 2026 per HUMA's latest filing, from $14.6 million in the prior quarter.
- Across five years, Research & Development topped out at $23.8 million in Q2 2024 and bottomed at $14.6 million in Q4 2025.
- Historically, Research & Development has averaged $18.7 million across 5 years, with a median of $18.6 million in 2023.
- Annual changes were most pronounced in 2023 — Research & Development surged 40.19% — and 2025, when it dropped 29.29%.
- Humacyte's Research & Development stood at $15.0 million in 2022, then soared by 34.92% to $20.2 million in 2023, then rose by 2.36% to $20.7 million in 2024, then decreased by 29.29% to $14.6 million in 2025, then surged by 33.26% to $19.5 million in 2026.
- Business Quant data shows HUMA's Research & Development at $19.5 million in Q1 2026, $14.6 million in Q4 2025, and $17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 18.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.14 Mn |
| Mar 31, 2026 | 19.46 Mn |
| Dec 31, 2025 | 14.61 Mn |
| Sep 30, 2025 | 17.27 Mn |
| Jun 30, 2025 | 22.01 Mn |
| Mar 31, 2025 | 15.42 Mn |
| Dec 31, 2024 | 20.66 Mn |
| Sep 30, 2024 | 22.93 Mn |
| Jun 30, 2024 | 23.75 Mn |
| Mar 31, 2024 | 21.26 Mn |
| Dec 31, 2023 | 20.18 Mn |
| Sep 30, 2023 | 18.55 Mn |
| Jun 30, 2023 | 20.54 Mn |
| Mar 31, 2023 | 17.28 Mn |
| Dec 31, 2022 | 14.96 Mn |
| Sep 30, 2022 | 17.34 Mn |
| Jun 30, 2022 | 14.65 Mn |
| Mar 31, 2022 | 16.31 Mn |
| Dec 31, 2021 | 16.25 Mn |
| Sep 30, 2021 | 15.39 Mn |